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Abstract
Background: Traumatic brain injury initiates biochemical processes that lead to secondary neurodegeneration.
Imaging studies suggest that tissue loss may continue for months or years after traumatic brain injury in
association with chronic microglial activation. Recently we found that metabotropic glutamate receptor 5 (mGluR5)
activation by (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) decreases microglial activation and release of associated
pro-inflammatory factors in vitro, which is mediated in part through inhibition of reduced nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase. Here we examined whether delayed CHPG administration reduces
chronic neuroinflammation and associated neurodegeneration after experimental traumatic brain injury in mice.
Methods: One month after controlled cortical impact traumatic brain injury, C57Bl/6 mice were randomly assigned
to treatment with single dose intracerebroventricular CHPG, vehicle or CHPG plus a selective mGluR5 antagonist, 3-
((2-Methyl-4-thiazolyl)ethynyl)pyridine. Lesion volume, white matter tract integrity and neurological recovery were
assessed over the following three months.
Results: Traumatic brain injury resulted in mGluR5 expression in reactive microglia of the cortex and hippocampus
at one month post-injury. Delayed CHPG treatment reduced expression of reactive microglia expressing NADPH
oxidase subunits; decreased hippocampal neuronal loss; limited lesion progression, as measured by repeated T2-
weighted magnetic resonance imaging (at one, two and three months) and white matter loss, as measured by
high field ex vivo diffusion tensor imaging at four months; and significantly improved motor and cognitive recovery
in comparison to the other treatment groups.
Conclusion: Markedly delayed, single dose treatment with CHPG significantly improves functional recovery and
limits lesion progression after experimental traumatic brain injury, likely in part through actions at mGluR5
receptors that modulate neuroinflammation.
Keywords: Traumatic brain injury, microglia, metabotropic glutamate receptor 5, delayed treatment,
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Background
Traumatic brain injury (TBI) causes cell death and neu-
rological dysfunction through both direct physical dis-
ruption of tissue or pathways (primary injury), as well as
delayed and potentially reversible molecular and cellular
pathophysiological mechanisms (secondary injury)
resulting in progressive white matter and grey matter
damage [1]. Such delayed injury begins within seconds
to minutes after the insult and may continue for days,
weeks or potentially months to years [2]. These pro-
cesses are characterized by neuronal cell death, as well
as infiltration and activation of blood-borne immune
cells, such as macrophages and lymphocytes, and activa-
tion of resident microglia [3].
After TBI, microglia become activated and undergo
marked changes in cell morphology and behavior. Upon
activation, microglia contract their processes and
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phology, followed by proliferation and migration
towards the site of injury [4]. Activated microglia can
secrete a large number of factors, including cytokines,
chemokines and other pro-inflammatory substances (for
example, nitric oxide, prostaglandins and superoxide)
that are toxic to neurons [5,6]. Microglial-mediated
inflammation has been implicated as an important
mechanism contributing to progressive neurodegenera-
tion in multiple chronic neurological disorders [7]. Ani-
mal and clinical studies indicate that post-traumatic
neuroinflammation persists for months to years after
brain injury [8-11], and may contribute to chronic neu-
rodegeneration and related significant neurological defi-
cits [12-15].
We have previously identified a cluster of microglial
associated genes and associated proteins that are chroni-
cally expressed after central nervous system (CNS)
trauma [16], including membrane subunits of the
reduced nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase enzyme. NADPH oxidase amplifies
pro-inflammatory gene expression in activated microglia
and promotes microglial-mediated neurotoxicity [17],
and may be a key driving factor for the chronic progres-
sion of neurodegenerative disease [18]. More recently,
we demonstrated that microglia in culture and in the
rodent CNS express receptors for metabotropic gluta-
mate receptor 5 (mGluR5). Activation of mGluR5 using
the specific agonist (RS)-2-chloro-5-hydroxyphenylgly-
cine (CHPG) inhibits microglial activation and the
release of inflammatory factors, in part by inhibiting
NADPH oxidase [19-21].
In the present studies we show that mGluR5 is
chronically expressed in reactive microglia following
controlled cortical impact (CCI) induced TBI in mice,
a n dt h a ts i n g l ed o s eC H P Ga d m i n i s t r a t i o no n em o n t h
after TBI inhibits subsequent chronic post-injury inflam-
mation and reduces the number of highly activated
microglia that express NADPH oxidase. Such markedly
delayed treatment also significantly reduces late tissue
loss after TBI and improves long-term sensorimotor and
cognitive recovery. As this effect is blocked by concur-
rent systemic administration of a selective mGluR5
receptor antagonist, the therapeutic actions of CHPG
reflect actions at mGluR5 receptors.
Methods
Controlled cortical impact injury
All surgical procedures were carried out in accordance
with protocols approved by Georgetown University
Medical Center Institutional Animal Care and Use
Committee. Our custom-designed CCI injury device
[22] consists of a microprocessor-controlled pneumatic
impactor with a 3.5 mm diameter tip. Male C57Bl/6
mice (20 to 25 g) were anesthetized with isoflurane eva-
porated in a gas mixture containing 70% N2Oa n d3 0 %
O2 and administered through a nose mask (induction at
4% and maintenance at 2%). Depth of anesthesia was
assessed by monitoring respiration rate and pedal with-
drawal reflexes. Mice were placed on a heated pad and
their core body temperature was maintained at 37°C.
The head was mounted in a stereotaxic frame, and the
surgical site was clipped and cleaned with Nolvasan and
ethanol scrubs. A 10-mm midline incision was made
over the skull, the skin and fascia were reflected, and a
4-mm craniotomy was made on the central aspect of
the left parietal bone. The impounder tip of the injury
device was then extended to its full stroke distance (44
mm), positioned to the surface of the exposed dura, and
reset to impact the cortical surface. Moderate-level
injury was induced using an impactor velocity of 6 m/s
and deformation depth of 2 mm as previously described
[23]. After injury, the incision was closed with inter-
rupted 6-0 silk sutures, anesthesia was terminated, and
the animal was placed into a heated cage to maintain
normal core temperature for 45 minutes post-injury. All
animals were monitored carefully for at least 4 hours
after surgery and then daily. Sham animals underwent
the same procedure as injured mice except for the
impact.
Drug treatment
One month post-injury, mice received a single intracer-
ebroventricular (icv) injection of CHPG or equal volume
vehicle. A 10 mM solution (saline with 1% dimethyl
sulfoxide) was injected into the left ventricle (coordi-
nates from bregma = anteroposterior: -0.5, lateral: -1.0;
ventral: -2.0) using a 30 gauge needle attached to a
Hamilton syringe at a rate of 0.5 μL/min, with a final
volume of 5 μL, or 50 nmols of CHPG. Fifteen minutes
prior to CHPG administration, one group of mice
received the selective mGluR5 antagonist 3-((2-Methyl-
4-thiazolyl)ethynyl)pyridine (MTEP; 10 mg/kg in saline)
by intraperitoneal injection. All other mice received an
equal volume vehicle intraperitoneal injection. Dosages
were based upon prior investigations in spinal cord
injury and TBI models [20,24].
In vivo magnetic resonance imaging
One, two and three months after CCI, brain lesion
volume was assessed using T2-weighted magnetic reso-
nance imaging (MRI) as previously described [23] (n = 6
per group). Briefly, anesthetized animals were placed in
a heated plexiglass holder and a respiratory motion
detector positioned over the thorax to facilitate respira-
tory gating. The plexiglass holder was then placed in the
center of the 7 Tesla magnet bore (Bruker Medical Inc.,
Billerica, MA, USA) where a 72-mm proton-tuned
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the brain was optimized and a sagittal scout image was
acquired (rapid acquisition relaxation enhancement
(RARE) pulse sequence image; field of vision, 4 × 4 cm;
128 × 128 resolution; repetition time (TR) to echo time
(TE), 1,500/10 ms with a RARE factor of 8, making the
effective TE 40 ms). Multi-slice, multi-echo T2-weighted
images were acquired using the following parameters:
field of vision, 3 × 3 cm; 256 × 256 resolution; TR to
TE, 1,500/10 ms; RARE factor of 8; TE, 40 ms; 10 ×
slices; slice thickness, 0.75 mm. Lesion volume was
quantified from the summation of areas of hyperinten-
sity on each slice, multiplied by slice thickness, for both
the ipsilateral and contralateral hemispheres. Contralat-
eral volumes were subtracted from ipsilateral volumes to
obtain TBI-induced lesion volumes.
Ex vivo diffusion tensor imaging
Ex vivo diffusion tensor imaging (DTI) was performed
four months post-injury on formalin-perfused brain (n =
5 per group). DTI imaging was performed with a 9.4
Tesla NMR spectrometer (Bruker Biospin, Billerica, MA,
USA) equipped with a Micro2.5 gradient system (100 G/
cm maximum gradient strength). We used our recently
developed diffusion weighted gradient and spin echo
sequence [25] with the following parameters: TE, 33 ms;
TR, 900 ms; number of radio frequency pulses (Nrf) =
4; bandwidth, 100 kHz; and four signal averages. The
imaging field of view and matrix size were 13.0 × 10.0 ×
18.4 mm and 128 × 96 × 180 mm respectively, and the
native resolution was approximately 100 × 100 × 100
μm
3. The spectral data were apodized by a symmetric
trapezoidal function with 10% ramp widths and zero-
filled before Fourier transformation. For DTI, eight dif-
fusion directions (b-value 1700 s/mm
2), and two non
diffusion-weighted images were acquired with δ =3m s ,
Δ = 15 ms. The total imaging time was 11 hours. The
signal-to-noise ratios in the corpus callosum measured
in the non diffusion-weighted images were greater than
40 for all experiments.
Image processing
For the ex vivo results, an average diffusion-weighted
image (aDW) was obtained by averaging the six diffu-
sion-weighted images. Signals from skull tissues in the
aDW images were manually removed. The diffusion ten-
sor was calculated using a log-linear fitting method
[26,27]. The fractional anisotropy (FA), primary eigen-
vector (v1), parallel diffusivity (l║, the primary eigenva-
lue) and perpendicular diffusivity (l┴, the average of the
secondary and tertiary eigenvalues) were calculated on a
voxel-by-voxel basis from diffusion tensor using DTIStu-
dio http://www.mristudio.org[28]. The in vivo and ex
vivo aDW images were first rigidly aligned to our ex
vivo MRI based atlases [29], respectively, using the six-
parameter rigid registration function in the automated
image registration package [30,31].
Motor and cognitive function testing
Motor performance was assessed one, two and three
months post-injury using the beam walk task, as pre-
viously described [22] (n = 7 (vehicle), 7 (CHPG), 4
(MTEP + CHPG)). Briefly, mice were trained to cross a
narrow wooden beam 6 mm wide and 120 cm in length,
which was suspended 300 cm above a 60-mm thick
foam rubber pad. The number of foot-faults for the
right hind limb was recorded over 50 steps and a basal
level of competence at this task was established before
surgery with an acceptance level of < 10 faults per 50
steps. Spatial learning and memory was assessed using
an acquisition paradigm of the Morris water maze
(MWM) test three and a half months post-injury as
described [32] (n = 4 (naïve), 8 (vehicle), 8 (CHPG), 8
(MTEP + CHPG)). A white circular pool was divided
into four quadrants using computer-based AnyMaze
video tracking system (Stoelting Co., Wood Dale, IL,
USA) and the platform was hidden in one quadrant
(south-west) 35.56 cm from the side-wall. Spatial learn-
ing and memory performance was assessed by determin-
ing the latency (seconds) to locate the sub-merged
hidden platform with a 90-second limit per trial. On the
day after the MWM acquisition test reference spatial
memory was assessed by a probe trial; the time spent
(seconds) within a 60-second limit in the quadrant
where the platform had been hidden during acquisition
phase was recorded. A visual cue test was performed
using a flagged platform placed on the platform in one
of the quadrants (with a 90-second limit per trial) and
latency (seconds) to locate the flagged platform was
recorded. In addition, the Water maze search strategies
employed by each animal during the acquisition trials of
the MWM test were analyzed as previously described
[33]. Briefly, three strategies were identified and categor-
ized: spatial strategy was defined as swimming directly
to the platform in no more than one loop or swimming
directly to the correct target quadrant and searching;
systematic strategy was defined as searching the interior
portion of or entire tank without spatial bias, and
searching incorrect target quadrant; and looping strategy
was defined as circular swimming around the tank,
swimming in tight circle, and/or swimming around the
wall of tank.
Unbiased stereological assessment of cortical microglia
At the indicated time points, mice were anesthetized
(100 mg/kg sodium pentobarbital, intraperitoneal injec-
tion) and transcardially perfused with 100 mL of 0.9%
saline followed by 300 mL of 4% paraformaldehyde (10%
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PA, USA) (n = 5 per group). The brain was removed
and post-fixed in 4% paraformaldehyde overnight and
cryoprotected in 30% sucrose. Coronal sections were cut
(three × 60 μm followed by three × 20 μm sections) and
serially collected throughout the injured brain, starting
at +1.78 mm from the bregma. Sections were mounted
onto glass slides for immunohistochemical analysis.
Microglia were immunostained with anti-ionized cal-
cium binding adaptor molecule 1 (Iba-1) (1:1000; Wako
Chemicals, Richmond, VA, USA) for 1 hour, washed in
PBS and incubated with biotinylated anti-rabbit immu-
noglobulin G antibody (Vector Laboratories, Burlin-
game, CA, USA) for 2 hours at room temperature.
Sections were placed in avidin-biotin-horseradish perox-
idase solution, diluted according to the manufacturer’s
instructions for 1 hour (Vectastain elite ABC kit, Vector
Laboratories) and then reacted with 3,3’- diaminobenzi-
dine (Vector Laboratories) for color development. Sec-
tions were counterstained with cresyl violet (FD
NeuroTechnologies, Baltimore, MD, USA), dehydrated
and mounted for analysis.
Stereoinvestigator software (MBF Biosciences, Willis-
ton, VT, USA) was used to count the number of cortical
microglia in each of the three microglial morphological
phenotypes (ramified, hypertrophic and bushy) using the
optical fractionator method of unbiased stereology. The
sampled region was the perilesional ipsilateral cortex
between -1.22 mm and -2.54 mm from the bregma.
Every fourth 60-μm section was analyzed beginning
from a random start point. Sections were analyzed using
a Leica DM4000B microscope (Leica Microsystems,
Exton, PA, USA). The optical dissector had a size of 50
×5 0μm in the x and y-axis with a height of 10 μm and
guard zone of 4 μm from the top of the section. Dissec-
tors were positioned every 150 μm in the x and y-axis.
Microglial phenotypic classification was based on the
length and thickness of the projections, the number of
branches and the size of the cell body as previously
described [34]. Neurolucida software (MBF Biosciences)
was used to trace and quantify the size of microglial cell
bodies and dendrites at different stages of activation fol-
lowing injury. Microglia were outlined using the live
image setting so that the width of the dendrites could
be traced while focusing on the section. The cell body
was outlined using the contour tool followed by the tra-
cing of the individual dendrites, using the dendrite line
tool. A quick measure tool quantified the average thick-
ness of each microglial branch. Neurolucida explorer
software was used to determine the cell body area and
volume, and dendrite length and branching number.
Ramified microglia possessed long thin processes (> 650
μm in length), had a small cell body volume (< 10 μm
3)
and many branches (20 to 30). Hypertrophic microglia
possessed medium length processes (300 to 550 μmi n
length), had larger cell body volumes (50 to 75 μm
3)
and many branches (20 to 30). Bushy microglia pos-
sessed short thick processes (< 200 μm in length), had a
larger cell body volume (80 to 100 μm
3)a n dv e r yf e w
branches (< 10). The volume of the region of interest
was measured using a Cavalieri estimator method with a
grid spacing of 100 μm. The estimated number of
microglia in each phenotypic class was divided by the
volume of the region of interest to obtain the cellular
density expressed in cells per cubic millimeter.
Unbiased stereological counting of surviving
hippocampal neurons
The stereoinvestigator software was used to count the
total number of surviving neurons in the Cornu Ammo-
nis (CA) 1, CA3 and dentate gyrus subfields of the hip-
pocampus using the optical fractionator method of
unbiased stereology. The sampled region for each hippo-
campal subfield was demarcated in the injured hemi-
sphere and cresyl violet neuronal cell bodies were
counted. The volume of the hippocampal subfield was
measured using a Cavalieri estimator method. The esti-
mated number of surviving neurons in each field was
divided by the volume of the region of interest to obtain
the cellular density expressed in cells per cubic
millimeter.
Immunohistochemistry
Immunohistochemistry was performed on 20-μms e c -
tions and standard immunostaining techniques were
employed. The following primary antibodies were used:
rabbit anti-Iba-1 (1:500, cat. no. 019-19741, Wako Che-
micals), mouse anti-mGluR5, clone 464823 (1:100; cat.
no. MAB45141, R&D Systems, Minneapolis, MN, USA),
rat anti-ED1 (1:200, cat. no. MCA1957G, AbD Serotec,
Raleigh, NC, USA), and mouse anti-gp91
phox (1:200, cat.
no. 611415, BD Transduction Inc., Franklin Lakes, NJ,
USA). Counterstaining was performed with 4’,6 - d i a m i -
dino-2-phenylindole (1 μg/mL; Sigma-Aldrich, St. Louis,
MO, USA). Fluorescence microscopy was performed
using a LEICA (TCS SP5 II) confocal microscope system
(Leica Microsystems).
Statistical analysis
Lesion volume, functional data and unbiased stereologi-
cal analysis were performed by an investigator blinded
to treatment group. Quantitative data were expressed as
mean ± standard errors of the mean (SEM). Functional
data for beam walk and acquisition phase of MWM
were analyzed by repeated measures (trial and time)
one-way (groups) analysis of variance (ANOVA) to
determine the interactions of post-injury trial and
groups, followed by post-hoc adjustments using
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was analyzed using a chi-square analysis. The T2-
weighted MRI analysis was analyzed by two-way
ANOVA, followed by post-hoc adjustments using Bon-
ferroni t-test. Remaining data were analyzed using
Mann-Whitney U test, Student’s t test or one-way
ANOVA, where appropriate. The functional data was
analyzed using SigmaPlot 12 (Systat Software, San Jose,
CA, USA). All other statistical tests were performed
using the GraphPad Prism Program, Version 3.02 for
Windows (GraphPad Software, San Diego, CA, USA). P
< 0.05 was considered statistically significant.
Results
mGluR5 is expressed in chronically activated microglia
after traumatic brain injury
After TBI, microglia undergo dramatic changes in cell
morphology and behavior, transforming from a resting
status that have a ramified cellular morphology to highly
reactive cells that have a dense and enlarged amoeboid-
like cell morphology (bushy or hypertrophic) and up-
regulate cell surface antigens such as CD68 or ED1. We
have recently demonstrated that microglial activation is
associated with progressive neurodegeneration up to 21
days post-TBI [35], and that mGluR5 is expressed in
cultured microglia [19,21] and co-localizes with micro-
glia in a rodent model of spinal cord injury [20].
In order to evaluate mGluR5 expression levels in
chronically activated microglia, C57Bl/6 mice underwent
moderate-level CCI TBI or sham surgery and samples
were collected one month after TBI for immunohisto-
chemical analysis. mGluR5 expression was undetectable
in resting microglia that displayed a ramified cellular
morphology in the cortex and hippocampus of sham-
injured samples (Figure 1A, B). In contrast, mGluR5
expression was up-regulated in highly reactive microglia
that displayed a hypertrophic or bushy cellular morphol-
ogy and co-expressed ED1 cell-surface antigens in the
cortex and hippocampus of one-month TBI samples.
Notably, the membrane bound component of the
NADPH oxidase enzyme, gp91
phox, co-localized with
ED1-positive reactive microglial in the injured cortex at
one month post-injury (Figure 1C), indicating chronic
expression of NADPH oxidase in microglia following
TBI.
Delayed administration of CHPG reduces lesion volume
and increases white matter integrity after traumatic brain
injury
Given that microglia are chronically activated and
express NADPH oxidase after TBI, we hypothesized that
markedly delayed inhibition of selected inflammatory
pathways may attenuate microglial-mediated inflamma-
tion and reduce progressive neurodegeneration after
brain trauma. Previously we demonstrated that the
selective mGluR5 agonist, CHPG, inhibits microglial
activation and the release of associated inflammatory
factors in vitro,i np a r tm e d i a t e db yi n h i b i t i o no f
NADPH oxidase [19,21]. Therefore, at one month post-
injury, TBI mice underwent T2-weighted MRI to assess
lesion volume and were subsequently randomized prior
to treatment to insure that all groups had comparable
lesion volumes (at one month post-injury: vehicle = 8.8
±1 . 7m m
3, CHPG = 8.0 ± 2.7 mm
3,M T E P+C H P G=
8.7 ± 1.0 mm
3, mean ± SEM). After randomization, TBI
mice were administered one of three treatment regimens
at one month post-TBI: a single dose icv injection of
CHPG; equal-volume vehicle (saline); or intraperitoneal
injection of MTEP (mGluR5 antagonist) prior to icv
CHPG administration. In vehicle-treated TBI mice, the
lesion volume expanded significantly between one and
three months post-injury (Figure 2A; P =0 . 0 1 6 ) ,
increasing to 190% of one-month (pre-treatment) values,
indicating progressive lesion expansion over time. In
contrast, CHPG treatment arrested the expansion of the
lesion over time with lesion volumes at three months
post-injury not significantly different from one-month
(pre-treatment) values. Moreover, at three months post-
injury, CHPG-treated TBI mice had significantly
reduced lesion volumes when compared to vehicle-trea-
ted TBI mice (Figure 2A; vehicle-treated TBI = 16.8 ±
1.9 mm
3 versus CHPG-treated TBI 7.7 ± 2.0 mm
3, P =
0.010). In the negative control group, administration of
t h em G l u R 5a n t a g o n i s tM T E P1 5m i n u t e sp r i o rt o
CHPG treatment prevented the beneficial effects of
CHPG, with lesion volumes of MTEP + CHPG-treated
mice not significantly different to vehicle-treated mice
(Figure 2A; MTEP + CHPG-treated TBI = 12.66 ± 2.5
mm
3). Similar trends were detected two months post-
injury but did not reach statistical significance (vehicle-
treated TBI = 10.02 ± 1.9 mm
3, CHPG-treated TBI 7.6
±2 . 4m m
3, MTEP + CHPG-treated TBI = 9.128 ± 1.3
mm
3). Representative MRI images from each treatment
group at three months post-injury are presented in Fig-
ure 2B.
Ex vivo DTI using a 9.4 Tesla NMR spectrometer ima-
ging system was performed four months post-injury to
analyze white matter tract integrity in TBI mice. TBI
increased mean diffusivity and decreased FA in vehicle-
treated TBI mice, whereas delayed CHPG treatment sig-
nificantly reduced mean diffusivity (Figure 2Cii; P =
0.032) and increased FA (Figure 2Ciii; P = 0.048) in
CHPG-treated TBI mice, suggesting significant sparing
of white matter tracts at four months post-TBI. Further
analysis revealed that CHPG treatment significantly
increased the external capsule fiber volume after TBI
(Figure 2D; vehicle-treated TBI = 1.4 ± 0.3 mm
3 versus
CHPG-treated TBI = 3.1 ± 0.7 mm
3, mean ± SEM, P=
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Page 5 of 15Figure 1 mGluR5 is expressed in chronically activated microglia at one month post TBI. (A and B) mGluR5 expression was evaluated in
the cortex (A) and hippocampus (B) of sham or TBI brains at one month post-injury. Iba-1 (green) and ED1 (magenta) labeled activated
microglia. mGluR5 expression (red) was undetectable in resting microglia that displayed a ramified cellular morphology, but was strongly up-
regulated in highly reactive microglia that displayed a hypertrophic or bushy cellular morphology and co-expressed ED1 (merged). (C) The
membrane bound component of the NADPH oxidase enzyme, gp91
phox (red), co-localized (merged) with ED1-positive reactive microglial (green)
at one month post-TBI. Bar = 25 μm.
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Page 6 of 15Figure 2 Delayed treatment with the mGluR5 agonist, CHPG, reduces lesion volume and increases white matter integrity after TBI. (A)
Lesion volume was assessed using T2-weighted MRI in TBI mice. One month post-injury, all TBI mice had significant and comparable lesions
volumes and were subsequently randomized and treated with vehicle, CHPG or MTEP + CHPG. TBI-induced lesion volumes significantly
increased over three months in the vehicle-treated TBI group (*P < 0.05 versus one month), whereas the lesions in the CHPG-treated TBI group
did not expand and were significantly reduced at three months post-injury when compared to the vehicle-treated TBI group (+P < 0.05 versus
vehicle). TBI mice that received MTEP co-administration with CHPG had lesion volumes that were not significantly different compared to vehicle-
treated TBI levels (n = 6 per group). (B) Representative MRI images show hyperintense lesion areas from the lesion epicenter and rostral/caudal
regions at three months post-injury for each treatment group. (C) Ex vivo DTI was performed at four months post-injury. White matter tracts of
interest were outlined in either color or FA images (Ci) on both the ipsilateral (pink) and contralateral (brown) sides. The ratio of the ipsilateral
mean diffusivity (Cii) and FA (Ciii) to contralateral measurements demonstrate that CHPG treatment significantly reduced mean diffusivity and
increased FA (*P < 0.05, n = 5). (D) White matter tracts were outlined (Di) to determine fiber volume (Diii). Three-dimensional visual
representations are presented in (Dii). A naïve sample demonstrates the standard volume of white matter tracts in uninjured tissue. TBI resulted
in a marked reduction in white matter volume. Fiber volume was significantly increased in CHPG-treated TBI tissue when compared to vehicle-
treated TBI tissue (*P < 0.05, n = 5). Statistical analysis was by two-way ANOVA with Bonferroni t-test post-hoc corrections in (A), Mann-Whitney
U test in (Cii), and Student’s t-test in (Ciii) and (Diii). Bars represent mean ± SEM.
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with the mGluR5 agonist CHPG at one month post-TBI
resulted in improved structural integrity and preserved
white mater tracts at four months post-TBI.
Delayed treatment with CHPG improves functional
recovery after traumatic brain injury
In order to evaluate the long-term therapeutic benefit of
delayed administration of the mGluR5 agonist on TBI-
induced neurological impairments, we performed motor
and cognitive functional testing through the four
months post-injury. Functional assessment of fine motor
c o - o r d i n a t i o nw a sp e r f o r m e da to n e ,t w oa n dt h r e e
months after TBI using a beam walk test. Prior to treat-
ment at one month post-TBI, all groups of mice had
comparable motor function deficits (Figure 3A). Vehi-
cle-treated TBI mice failed to improve motor perfor-
mance at two or three months post-injury; in contrast,
CHPG-treated TBI mice showed significant motor func-
tion recovery at both time points in the beam walk task
(Figure 3A; successful foot placements at three months
post-injury: vehicle-treated TBI = 39.3 ± 5.1% versus
CHPG-treated TBI = 66.5 ± 5.7%, mean ± SEM, P <
0.05). Furthermore, MTEP pre-treatment blocked this
effect, with MTEP + CHPG-treated TBI mice perform-
ing identically to vehicle-treated mice throughout.
A one-day MWM test [32] was performed at three
and a half months post-TBI to assess spatial learning
and memory. The interaction of ‘post-injury trial x
groups’ (F(9,92) = 0.663, P = 0.74) was not statistically
significant. However, the factors of ‘post-injury trial’ (F
(3,92) = 5.032, P =0 . 0 0 3 )a n d‘groups’ (F(3,92) = 5.731,
P = 0.001) were found to be significant. Vehicle- and
MTEP + CHPG-treated TBI mice performed poorly in
this cognitive task, showing considerably increased
latency to find the hidden platform in trial 4 when com-
pared with uninjured, naïve mice (Figure 3B; P =0 . 0 0 8
(vehicle), P = 0.016 (MTEP + CHPG), versus naïve).
CHPG-treated TBI mice showed improvements in cog-
nitive performance with significantly reduced latency to
find the submerged platform in trial 4 when compared
with vehicle-treated TBI mice (P = 0.024, versus vehi-
cle). Reference memory was assessed using a probe trial
on the day following the MWM acquisition trials and
time for first entry into the target quadrant in which the
platform was originally placed was recorded. CHPG-
treated TBI mice had significantly reduced latency into
the target quadrant when compared to vehicle-treated
TBI mice (Figure 3C; P < 0.01), indicating reduced
retention memory deficits in the probe trial. Swim
speeds did not differ across groups (Figure 3D) and all
mice performed well in the visual cue test (data not
shown).
In order to assess the search strategies utilized by
mice to find the hidden platform, the swimming pattern
for each mouse was analyzed and assigned a search
strategy (spatial, systematic or looping) [33]. The com-
parison of search strategies between groups was per-
formed by chi-square analysis. Vehicle-treated and
MTEP + CHPG-treated TBI mice displayed diminished
spatial and systematic search strategies and increased
looping strategy compared to naïve or CHPG-treated
TBI mice (Figure 3E; P <0 . 0 5 ,
c2 = 16.35). Taken
together, the behavioral data indicate that delayed
CHPG administration improves motor and cognitive
recovery following TBI through an mGluR5-mediated
mechanism.
Delayed treatment with CHPG reduces the number of
activated microglial in the injured cortex and attenuates
hippocampal neurodegeneration at four months post-
injury
Following completion of the behavioral and in vivo MRI
studies, TBI mice were euthanized, their brains fixed
and coronal sections cut for histological studies. Iba-1
immunohistochemistry was performed to label microglia
in the injured brain. Based on cell morphological fea-
tures, microglia can be classified into three categories
corresponding to increasing activation status: ramified
(resting), hypertrophic and bushy [34,36,37]. Ramified
microglia have small cell bodies and thin, long and
highly branched processes (Figure 4A). In contrast,
hypertrophic microglia have larger cell bodies, with
thicker, shorter and highly branched processes, whereas
bushy microglia have multiple short processes that form
thick bundles around enlarged cell bodies (Figure 4A).
CNS injuries, such as stroke and TBI, cause transforma-
tion of resting ramified microglia into more active phe-
notypes, such as hypertrophic and bushy forms [34,35].
We performed an unbiased stereological assessment of
microglial cell number and activation phenotype in the
injured cortex of each group of mice at four months
post-TBI. Our data showed that despite an equal num-
ber of total microglia in each treatment group there was
a significantly reduced number of reactive hypertrophic
and bushy microglia in the cortex of CHPG-treated TBI
mice when compared to vehicle-treated TBI mice (Fig-
ure 4B; P < 0.01).
We then performed triple immunofluorescence stain-
ing for reactive microglia (Iba-1/ED1-positive) that
expressed NADPH oxidase (gp91
phox-positive) in the
four month vehicle-treated and CHPG-treated TBI sam-
ples (Figure 5). gp91
phox was highly expressed in ED1-
positive microglia that displayed a hypertrophic or
bushy cellular morphology in the cortex adjacent to the
lesion in vehicle-treated TBI samples. Notably, there
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Page 8 of 15Figure 3 Delayed treatment with CHPG improves functional recovery after TBI. (A) Motor coordination was assessed using a beam walk
test in TBI mice at one, two and three months post-injury. All injured mice performed poorly on this task prior to treatment, with no significant
differences between treatment groups. At two and three months post-injury, CHPG-treated TBI mice showed a significant increase in the
number of correct hind limb placements when compared to vehicle-treated mice (*P < 0.05 versus vehicle). Co-administration of MTEP with
CHPG blocked CHPG-mediated improvements such that this group performed similar to vehicle-treated TBI mice (n = 7 (vehicle), 7 (CHPG), 4
(MTEP + CHPG)). (B) Spatial learning and memory was assessed using a one-day MWM protocol performed three and a half months post-TBI.
The latency to find the submerged hidden platform in trial 4 was significantly increased in vehicle- and MTEP + CHPG-treated TBI mice when
compared to naïve controls (P< 0.05 versus naïve). CHPG treatment significantly reduced the latency when compared to vehicle-treated TBI mice
(P < 0.05 versus vehicle) (n = 4 (naïve), 8 (vehicle), 8 (CHPG), 8 (MTEP + CHPG)). (C) One day after MWM mice performed a probe trial in which
the platform was removed and the time to enter the correct quadrant where the platform had been was measured. Vehicle-treated TBI mice
had significantly increased latency to first entry into target quadrant compared to naïve controls (P < 0.05 versus naïve). CHPG-treated TBI mice
had reduced retention memory deficits and had significantly reduced latency to first entry (P < 0.01 versus vehicle). (D) There were no
significant differences in swim speeds between any of the treatment groups throughout the trials. (E) The escape strategy in the MWM test was
analyzed, and the percent composition for each strategy (spatial, systematic and looping) demonstrated that vehicle- and MTEP + CHPG-treated
TBI mice had diminished spatial and systematic strategies and increased looping strategies compared to naïve or CHPG-treated TBI mice.
Statistical analyses were by repeated measures one-way ANOVA with Student-Newman-Keuls post-hoc corrections in (A) and (B), one-way
ANOVA with Student-Newman-Keuls post-hoc corrections in (C) chi-square analysis in (E). Bars represent mean ± SEM.
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Page 9 of 15Figure 4 CHPG treatment reduces the number of hypertrophic and bushy microglia in the injured cortex at four months post-injury.
(A) Representative Iba-1 immunohistochemical images displaying each microglial activation phenotype. Microglia was reconstructed using
Neurolucida software and classified into ramified, hypertrophic and bushy activation phenotypes based on cellular morphological features.
Analysis of the difference between the three activation phenotypes indicated marked changes in dendritic length (Ai), branch thickness (Aii),
number of branches (Aiii) and cell body volume (Aiv). ***P < 0.001 versus bushy,
###P < 0.001 versus ramified,
&P < 0.05 versus hypertrophic,
$P <
0.05 versus ramified, ^P < 0.05 versus bushy. (B) Unbiased stereological quantification of microglial cell number and activation phenotype in
each treatment group four months post-injury. There was no significant difference in the total number of microglia (Bi) in the injured cortex four
months post-injury. CHPG-treated TBI tissue had significantly reduced numbers of hypertrophic (Biii) and bushy (Biv) microglia when compared
to vehicle-treated TBI tissue, and increased numbers of ramified microglia (Bii). **P< 0.01 versus vehicle,(n = 5/group). MTEP + CHPG-treated TBI
tissue showed similar microglial phenotype profiles as the vehicle-treated TBI tissue, with fewer ramified microglia and more hypertrophic and
bushy phenotypes. Statistical analyses were by one-way ANOVA with Student-Newman-Keuls post-hoc corrections in (A) and (B). Bars represent
mean ± SEM.
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Page 10 of 15Figure 5 CHPG treatment attenuates NADPH oxidase expression in reactive microglia at four months post-injury. The NADPH oxidase
subunit, gp91
phox (red), co-localized (merged) with EDI-positive reactive microglial (magenta) that displayed a hypertrophic or bushy cell
morphology (Iba-1; green) in the injured cortex of vehicle-treated TBI samples four months post-TBI. CHPG-treated TBI samples has reduced
gp91
phox-positive reactive microglia at this time point. Bar = 25 μm.
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Page 11 of 15were fewer reactive microglia (ED1-positive) in the
CHPG-treated TBI samples and gp91
phox expression was
also markedly reduced in these cells. These data demon-
strate that delayed CHPG treatment selectively reduced
the activation of the highly reactive hypertrophic and
bushy microglia at four months post-TBI and reduced
the expression of NADPH oxidase in these cells.
Finally, we performed stereological assessment of sur-
viving neurons in the CA1, CA3 and dentate gyrus sub-
fields of the hippocampus at four months post-TBI to
evaluate post-traumatic neuronal loss. CHPG treatment
significantly reduced neuronal cell loss in the hippocam-
pus four months post-injury (Figure 6), with greater
numbers of surviving neurons when compared to vehi-
cle-treated and MTEP + CHPG-treated TBI groups.
Moreover, CHPG-treatment resulted in significantly
increase neuronal survival in the CA3 and dentate gyrus
subfields of the hippocampus when compared to the
vehicle-treated TBI group (Figure 5; CA3: 227,897 ±
7,363 (vehicle) versus 326,085 ± 10,203 (CHPG) counts/
mm
3, P < 0.001; dentate gyrus: 407,322 ± 14,244 (vehi-
cle) versus 683,886 ± 100,182 (CHPG) counts/mm
3, P <
0.05). The neuroprotective effects of CHPG treatment
were abolished by co-administration of the mGluR5
antagonist, MTEP (Figure 6; CA3: 207,661 ± 45,864
(MTEP + CHPG) counts/mm
3; dentate gyrus: 403,799 ±
52,466 (MTEP + CHPG) counts/mm
3, both P <0 . 0 5
versus CHPG-treated TBI group).
Discussion
Taken together, our data demonstrate chronic microglial
activation after experimental TBI, which may contribute
to the observed progressive neurodegeneration and tis-
sue loss that is associated with functional impairments.
Furthermore, they demonstrate that the temporal win-
dow for neuroprotective intervention after TBI is signifi-
cantly longer than generally believed. These
observations are consistent with prior experimental
work demonstrating progressive cortical damage and
increased NFB activation in macrophages and/or
microglia up to one year after trauma [12,38,39]. Pro-
longed microglial activation has been demonstrated
many months after TBI in humans [9] and increased
microglial activation has also been observed up to four
years after TBI in human post-mortem tissue [11].
We previously reported that CHPG treatment, acting
through mGluR5, reduces microglial activation and the
associated release of free radicals and pro-inflammatory
cytokines in microglial cell culture models (both primary
cultures and a mouse microglial cell line) after stimula-
tion with the classical activators lipopolysaccharide or
interferon-g [19,21]. CHPG treatment also abolished the
neurotoxic potential of activated microglia and reduced
NADPH oxidase activity in such in vitro models. These
effects of CHPG were blocked by knockout of the
mGluR5 receptor or by addition of the selective
mGluR5 antagonist MTEP, and reduced by co-incuba-
tion with siRNAs directed against either of the two
membrane subunits of NADPH oxidase [19]. The cur-
rent study supports these findings, as MTEP administra-
tion prior to CHPG treatment blocked its protective
actions.
Examining the injured cortex one month after TBI, we
demonstrated that mGluR5 expression was up-regulated
in activated microglia that co-expressed the phagocytic
marker, ED1, and exhibited a hypertrophic or bushy cel-
lular phenotype. The observed post-traumatic expression
of mGluR5 in activated microglia is consistent with pre-
vious in vivo studies demonstrating microglial mGluR5
expression at the lesion site in spinal cord injury and
excitotoxic brain injury models [20,40]. In response to
trauma, there is both microglial proliferation and activa-
tion, along with migration to the site of injury [41,42].
In contrast to the ramified appearance of resting micro-
glia, activated microglia undergo substantial morpholo-
gical changes, with reduction and thickening of
processes leading to a hypertrophic or bushy appearance
[34]. Although microglia are believed to have both neu-
rotoxic and neuroprotective properties [3,5,43],
Figure 6 Unbiased stereological quantification of hippocampal
neurons at four months post-injury. CHPG-treatment resulted in
significantly reduced TBI-induced total neuron (Ai) loss in the
hippocampus when compared to vehicle-treated samples. In
addition, CHPG-treatment significantly spared neurons in the CA3
(Aiii) and dentate gyrus (Aiv) sub-subfields of the hippocampus (*P
< 0.05, ***P < 0.001 versus vehicle; n = 3). In contrast, co-
administration of MTEP with CHPG reversed the neuroprotective
effects of CHPG-treatment in each hippocampal sub-field (+P < 0.05
versus CHPG). Statistical analysis was by one-way ANOVA with
Student-Newman-Keuls post-hoc corrections. Bars represent mean ±
SEM.
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matic inflammation can contribute to delayed cell and
tissue loss [35,44,45]. Indeed, microglial activation and
release of associated inflammatory factors has been pro-
posed as an important contributing factor for many
acute and chronic neurodegenerative disorders [7,46].
Here we demonstrate that delayed CHPG administra-
tion significantly reduced the number of microglia
showing the reactive bushy or hypertrophic phenotypes
associated with a pro-inflammatory and potentially neu-
rotoxic state [47]. Moreover, activated microglia
expressed the NADPH oxidase sub-unit, gp91
phox four
months post-injury, suggesting the chronic expression of
NADPH oxidase in these cells; these data are consistent
with the chronic up-regulation of expression of NADPH
oxidase sub-units in a microglial-associated gene cluster
six months after spinal cord injury [16]. Activated
microglia cause neuronal cell death in culture through
mechanisms that involves NADPH oxidase activation,
and this process is inhibited by CHPG treatment
[19,21]. Activated microglia also have been implicated in
chronic functional deficits after TBI in humans [9].
Recently, inhibition of NADPH oxidase has been shown
to reduce microglial activation in the post-ischemic
brain [48]. Notably, single dose CHPG administration
one month after TBI reduced the expression of NADPH
oxidase in reactive microglia at four months post-injury.
Together, these data suggest a positive activation feed-
back loop for neuroinflammation that contributes to
delayed neurodegeneration and related functional defi-
cits. Interruption of this positive feedback loop may
explain why even a single injection of CHPG adminis-
tered one month post-injury inhibits chronic neuroin-
flammation and limits functional loss in our model.
mGluR5 is also expressed in other cell types of the
CNS, such as neurons, astrocytes and oligodendrocytes
[49,50]. In addition to their anti-inflammatory effects,
group I mGluR agonists also reduce neuronal apoptosis
[51] as well as oligodendrocyte cell death [52]. Although
it is possible that anti-apoptotic effects of CHPG on
neurons or oligodendrocytes may have contributed to
the recovery observed in the current study, such apopto-
tic processes so late after injury are likely limited and,
given the half life of the compound, modulation of such
events would probably contribute minimally at best to
the improved outcome observed. In order to clarify the
mechanism underlying mGluR5-mediated neuroprotec-
tion after TBI, future studies will require cell specific
mGluR5 knockout in neurons, astrocytes, oligodendro-
cytes and microglia.
It is widely accepted that the therapeutic window for
limiting post-traumatic neurodegeneration after acute
brain injury is limited [53]. Indeed, most experimental
treatment studies for TBI have focused on the first
hours after injury [1]. With the recognition that more
delayed apoptotic mechanisms may contribute to injury
[54,55], the potential therapeutic window has been
expanded to perhaps 24 to 72 hours. Although it has
been shown experimentally and, more recently, clinically
that tissue loss after TBI may progress for months or
longer [12,14,15,56,57], there have been few attempts to
pharmacologically modify such markedly delayed neuro-
degeneration. Here we demonstrate that single dose
treatment one month after trauma significantly reduced
both histological changes and behavioral dysfunction
over a subsequent period of months. Considerable tissue
sparing was observed in hippocampal and cortical
regions after CHPG treatment, which was associated
with significant improvements in both sensorimotor
(beam walk) and cognitive (MWM) function.
Chronic neurological deficits are characteristic of
moderate to severe TBI, although such deficits may sta-
bilize or improve over time - likely reflecting endogen-
ous plasticity. The DTI studies extend the observations
from T2-weighted MRI by demonstrating significantly
better preservation of white matter tracks in the brain at
four months in the CHPG-treated TBI group as com-
pared to controls. DTI detects directionality of water
diffusion. After TBI, FA increases, whereas mean diffu-
sivity, or the directed diffusion of water, typically along
white matter tracks, is reduced [58,59]. These techni-
ques have been used to reflect the integrity of white
matter tracks (tractography) in the CNS [58]. FA has
been shown to be negatively correlated with deficits in
memory performance [59], consistent with our observa-
tions that CHPG treatment reduced this measure while
improving cognitive performance.
Conclusions
In summary, we demonstrate that markedly delayed
treatment with CHPG one month after TBI significantly
reduces subsequent lesion progression and white matter
damage, with marked improvement in sensorimotor and
cognitive function. Such delayed CHPG treatment
attenuates neurodegeneration in the CA3 and dentate
gyrus subfields of the hippocampus, areas that show sig-
nificant neuronal loss after TBI and are associated with
cognitive impairment after injury [35,60,61]. CHPG
administration significantly attenuates the activation
state of microglia in the injured cortex, although it did
not alter the total number of microglia. The fact that
co-administration of an mGluR5 antagonist blocked the
protective effects of CHPG indicates that its therapeutic
actions were specific and mediated by mGluR5 recep-
tors, consistent with our previously published in vitro
data [19,21].
This study significantly extends the currently accepted
therapeutic window for neuroprotection after head
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Page 13 of 15injury. It also provides mechanistic experimental support
for microglial-mediated chronic neurodegeneration after
TBI and introduces a novel therapeutic approach for
brain trauma. Given the therapeutic efficacy of delayed
CHPG treatment, and its ability to modify chronic neu-
roinflammatory processes after traumatic injury, similar
strategies might prove beneficial for other chronic neu-
rodegenerative disorders that show a significant inflam-
matory component.
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